753 reports of this reaction
4.4% of all GEFITINIB reports
#4 most reported adverse reaction
DEATH is the #4 most commonly reported adverse reaction for GEFITINIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 753 FDA adverse event reports linking GEFITINIB to DEATH. This represents approximately 4.4% of all 17,300 adverse event reports for this drug.
Patients taking GEFITINIB who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is moderately reported among GEFITINIB users, representing a notable but not dominant share of adverse events.
In addition to death, the following adverse reactions have been reported for GEFITINIB:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 753 FDA reports for GEFITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 4.4% of all adverse event reports for GEFITINIB, making it a notable side effect.
If you experience death while taking GEFITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.